文献速递淋巴瘤

FOXP1表达是接受利妥昔单抗联合化疗的滤泡性淋巴瘤的预后生物标志物

FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.
PubMed 文献 · Blood · 2017-11-09

本研究通过基因表达数据挖掘发现FOXP1在EZH2和MEF2B突变病例中下调,并用免疫组化在763例滤泡性淋巴瘤组织中评估FOXP1蛋白表达。在142例接受R-CVP训练队列和395例接受CHOP±利妥昔单抗验证队列中,高FOXP1表达与更短的FFS相关,且在免疫化疗患者中独立于FLIPI。

要点

  • 高FOXP1表达在训练队列中占54%,与5年FFS率降低相关(55% vs 70%)。
  • 验证队列中高FOXP1表达占63%,接受R-CHOP者FFS显著缩短(HR 1.95,P=.017)。
  • 高FOXP1表达对免疫化疗患者FFS的影响独立于FLIPI。

核心结论

  • FOXP1是基因突变的下游表型共性,可预测含利妥昔单抗方案后的结局。

研究设计与样本

  • 研究对763例组织活检进行FOXP1免疫组化评估;采用基于人群的142例接受利妥昔单抗、环磷酰胺、长春新碱和泼尼松(R-CVP)治疗的滤泡性淋巴瘤训练队列,以及包含395例接受环磷酰胺、多柔比星、长春新碱和泼尼松(CHOP)±利妥昔单抗治疗的临床试验验证队列进行结局相关性分析。

主要发现

  • FOXP1在EZH2和MEF2B突变病例中均显著下调。
  • 训练队列中76例(54%)标本FOXP1高表达(>10%),与5年无失败生存(FFS)率降低相关(55% vs 70%)。
  • 验证队列中248例(63%)患者FOXP1高表达,与接受R-CHOP治疗患者FFS显著缩短相关(HR 1.95;P=.017),但与接受CHOP治疗患者无显著相关(HR 1.15;P=.44)。
  • 高FOXP1表达对免疫化疗患者FFS的影响独立于滤泡性淋巴瘤国际预后指数(FLIPI)。
  • 高FOXP1表达与TP53突变、IRF4表达及类似暗区生发中心或活化B细胞的基因表达特征等分子特征相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Follicular lymphoma (FL) is a clinically and molecularly highly heterogeneous disease, yet prognostication relies predominantly on clinical tools. We recently demonstrated that integration of mutation status of 7 genes, including EZH2 and MEF2B, improves risk stratification. We mined gene expression data to uncover genes that are differentially expressed in EZH2- and MEF2B-mutated cases. We focused on FOXP1 and assessed its protein expression by immunohistochemistry (IHC) in 763 tissue biopsies. For outcome correlation, a population-based training cohort of 142 patients with FL treated with rituximab, cyclophosphamide, vincristine, and prednisone, and a clinical trial validation cohort comprising 395 patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) ± rituximab were used. We found FOXP1 to be significantly downregulated in both EZH2- and MEF2B-mutated cases. By IHC, 76 specimens in the training cohort (54%) had high FOXP1 expression (>10%), which was associated with reduced 5-year failure-free survival (FFS) rates (55% vs 70%). In the validation cohort, high FOXP1 expression status was observed in 248 patients (63%) and correlated with significantly shorter FFS in patients treated with R-CHOP (hazard ratio [HR], 1.95; P = .017) but not in patients treated with CHOP (HR, 1.15; P = .44). The impact of high FOXP1 expression on FFS in immunochemotherapy-treated patients was additional to the Follicular Lymphoma International Prognostic Index. High FOXP1 expression was associated with distinct molecular features such as TP53 mutations, expression of IRF4, and gene expression signatures reminiscent of dark zone germinal center or activated B cells. In summary, FOXP1 is a downstream phenotypic commonality of gene mutations and predicts outcome following rituximab-containing regimens.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Mottok A, Jurinovic V, Farinha P, et al. FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. Blood. 2017. PMID: 29122756. doi:10.1182/blood-2017-08-799080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。